🔗 Visit the ClinicalTrials.gov page for NCT01665391
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. | Drug Des Devel Ther | 2015 | 1.33 |
| 2 | Lupus nephritis: the evolving role of novel therapeutics. | Am J Kidney Dis | 2014 | 1.11 |
| 3 | Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. | Oncoimmunology | 2015 | 1.06 |
| 4 | Therapeutic targets for treating fibrotic kidney diseases. | Transl Res | 2014 | 0.88 |
| 5 | TGF-β Signaling in the Kidney: Pro-fibrotic and Protective Effects. | Am J Physiol Renal Physiol | 2016 | 0.81 |
| 6 | Interventions for focal segmental glomerulosclerosis in adults. | Cochrane Database Syst Rev | 2022 | 0.75 |